Department of Pathology, Institut de Pathologie Multisite, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Department of Pathology, Gustave Roussy Institute, Villejuif, France.
Virchows Arch. 2021 Oct;479(4):765-772. doi: 10.1007/s00428-021-03099-1. Epub 2021 Apr 14.
Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship between a strong adaptive immune response and a better prognosis in malignant solid tumors is widely known. Due to the low incidence of epithelioid malignant peritoneal mesothelioma (EMPM), very little is known about their immune micro-environment. We encountered several cases of tertiary lymphoid structures in EMPM in a previous study and aimed to investigate in the same series the prevalence, clinicopathological features, and the prognostic impact associated with tertiary lymphoid structures in EMPM (TLS-EMPM). Cases of EMPM, from 1995 to 2018, were retrieved from 7 French institutions from the RENAPE Network. The predictions in terms of overall survival (OS) and progression-free survival (PFS) of TLS-EMPM were analyzed. We report 52 cases of TLS-EMPM among a series of 138 cases of EMPM. TLS-EMPM was significantly associated with neoadjuvant chemotherapy, and was not a prognostic indicator for OS (p = 0.652) and PFS (p = 0.804) in our series. TLS is a component of the host immune response to EMPM significantly associated with neoadjuvant chemotherapy, but was not a predictor of prognosis for overall and progression-free survivals in this series. These findings provide another possible etiology for tertiary lymphoid structures.
上皮样间皮瘤是弥漫性恶性腹膜间皮瘤中最常见的亚型。在恶性实体瘤中，强烈的适应性免疫反应与更好的预后之间的关系是众所周知的。由于上皮样恶性腹膜间皮瘤（EMPM）的发病率较低，因此对其免疫微环境知之甚少。在之前的一项研究中，我们在 EMPM 中遇到了几个三级淋巴结构的病例，我们旨在研究同一系列中 EMPM 中的三级淋巴结构（TLS-EMPM）的流行率、临床病理特征以及与三级淋巴结构相关的预后影响。从 1995 年到 2018 年，从 RENAPE 网络的 7 个法国机构中检索到 EMPM 病例。分析了 TLS-EMPM 对总生存率（OS）和无进展生存率（PFS）的预测。我们在 138 例 EMPM 系列中报告了 52 例 TLS-EMPM 病例。TLS-EMPM 与新辅助化疗显著相关，但在我们的系列中，TLS-EMPM 不是 OS（p=0.652）和 PFS（p=0.804）的预后指标。TLS 是宿主对 EMPM 免疫反应的一个组成部分，与新辅助化疗显著相关，但在本系列中，它不是总生存和无进展生存的预后预测指标。这些发现为三级淋巴结构提供了另一种可能的病因。
